---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-010377"
form_type: "8-K"
ticker: "FHTX"
cik: "0001822462"
company_name: "Foghorn Therapeutics Inc."
filed_at: "2026-02-23T23:59:59+00:00"
generated_at: "2026-05-16T01:14:25.238222+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Foghorn Therapeutics appoints Ryan Maynard as CFO, replacing interim CFO Jeff Sacher

## Summary
- Ryan Maynard appointed CFO effective February 23, 2026; succeeds Jeff Sacher (interim CFO).
- Compensation: $510k base salary, 40% bonus target, $90k signing bonus, 400k share option grant.
- Maynard brings 25+ years experience; most recently CFO of Cara Therapeutics (2022-2025).
- Previously CFO at Rigel Pharmaceuticals, LetsGetChecked, and Blade Therapeutics; started career at Ernst & Young.
- Maynard raised over $1B in financings and executed reverse merger for Cara with Tvardi Therapeutics.

## SEC filing metadata
- accession: 0001628280-26-010377
- form_type: 8-K
- ticker: FHTX
- cik: 0001822462
- company_name: Foghorn Therapeutics Inc.
- filed_at: 2026-02-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822462/000162828026010377/0001628280-26-010377-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822462/000162828026010377/fhtx-20260223.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-010377
- JSON: https://secwatch.observer/filing/0001628280-26-010377.json
- Plain text: https://secwatch.observer/filing/0001628280-26-010377.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.